INVESTIGATION OF CIRCULATING SERUM microRNA-328-3p
AND microRNA-3135a EXPRESSION AS PROMISING NOVEL
BIOMARKERS FOR AUTISM SPECTRUM DISORDER Popov NT, Minchev DS, Naydenov MM, Minkov IN, Vachev TI *Corresponding Author: Assistant Professor Tihomir I. Vachev, Ph.D., Department of Plant Phisyology
and Molecular Biology, University of Plovdiv “Paisii Hilendarski,” 24 Tzar Assen Str., Plovdiv, Bulgaria.
E-mail: tiho9@abv.bg page: 5 download article in pdf format
|
Abstract
Circulating microRNAs (miRNAs) are emerging
as promising diagnostic biomarkers for autism spectrum
disorder (ASD), but their usefulness for detecting ASD
remains unclear. Nowadays, development of promising
biomarkers for ASD remains a challenge. Recently,
dysregulation of the miRNAs expression in postmortem
brain tissue, serum and peripheral blood, have been associated
with ASD. Circulating miRNAs are known to be
secreted by a number of different cells and can interpose
delivery of information into receiver cells, thus affecting
their functions. Based on this fact, it is supposed that
serum miRNAs could be a novel class of biomarkers for
prognosis or diagnosis of pathological disorders including
ASD. In the current research, we investigated whether
the expression patterns of circulating miRNAs showed
dysregulation in subjects diagnosed with ASD. Expression
levels of serum miR-328-3p and miR-3135a were
analyzed by quantitative reverse transcription polymerase
chain reaction (qRT-PCR) method of subjects diagnosed
with ASD in comparison with healthy control subjects.
Our data showed that miR-328-3p and miR-3135a were
substantially down-regulated in ASD patients than in those
of healthy control subjects. Moreover, target gene analysis
of altered serum miRNAs displayed that these molecules
targeted 162 genes denoted as unique validated targets in
the miRWalk database, 71 of which appear to participate
in biological pathways involved in synaptic pathways and
neurodegenerative condition such as Alzheimer, Huntington
and Parkinson diseases. Finally, the results strongly
suggested that dys-regulated serum miRNAs might be
involved in molecular pathways associated with ASD and
miR-328-3p and miR-3135a have the potential to be promising
novel biomarkers for ASD.
|
|
|
|
|
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|